REDUCING GLOBAL PERIOPERATIVE RISK
This resource center is jointly hosted by The American Journal of Medicine,
The American Journal of Cardiology, and the Canadian Journal of Cardiology.
key Findings
- Among 21,842 patients underwent noncardiac surgery and who had hsTnT measured, peak postoperative hsTnT during the first 3 days after surgery was significantly associated with 30-day mortality. Elevated postoperative hsTnT without an ischemic feature was also associated with 30-day mortality.
- Multivariable analysis demonstrated that compared with the reference group (peak hsTnT <5 ng/L), peak postoperative hsTnT levels of 20 to <65 ng/L, 65 to <1000 ng/L, and ≥1000 ng/L had 30-day mortality rates of 3.0%(123/4049; 95%CI, 2.6%-3.6%), 9.1% (102/1118; 95%CI, 7.6%-11.0%), and 29.6%(16/54; 95%CI, 19.1%-42.8%), with corresponding adjusted HRs of 23.63 (95%CI, 10.32-54.09), 70.34 (95% CI, 30.60-161.71), and 227.01 (95%CI, 87.35-589.92), respectively.
- An absolute hsTnT change of ≥5 ng/L was associated with an increased risk of 30-day mortality (adjusted HR, 4.69; 95%CI, 3.52-6.25). An elevated postoperative hsTnT (ie, 20 to <65 ng/L with an absolute change ≥5 ng/L or hsTnT ≥65 ng/L) without an ischemic feature was associated with 30-day mortality (adjusted HR, 3.20; 95%CI, 2.37-4.32).
- Among the 3904 patients (17.9%; 95%CI, 17.4%-18.4%) with MINS, 3633 (93.1%; 95%CI, 92.2%-93.8%) did not experience an ischemic symptom.
Key Term:
Tab Section:
Key Column Display :
Right Column
